IONS

Ionis Pharmaceuticals, Inc. (IONS) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Ionis Pharmaceuticals is a fully integrated commercial-stage biotechnology company focused on RNA-targeted therapeutics. The company operates as a single segment and currently markets seven medicines, including TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA. Key recent developments include the FDA approval and launch of TRYNGOLZA for severe hypertriglyceridemia (sHTG) in June 2026 and the ongoing commercialization of DAWNZERA for hereditary angioedema (HAE).

Key Financial Metrics

Note: Cash and Short-Term Investments calculated as Cash ($350.1M) + Short-term investments ($1,704.5M). Long-Term Debt includes 0% Notes due 2030 ($753.4M), 1.75% Notes due 2028 ($569.3M), and royalty liability ($562.6M).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 41% in Q2 2026 compared to Q2 2025. This was primarily driven by a significant drop in Research and Development (R&D) revenue, which fell from $349.3M to $149.3M. The prior year included a $280M upfront payment from Ono Pharmaceutical for the sapablursen license.
• Commercial Growth: Despite the R&D decline, commercial revenue increased 15% to $118.6M, driven by DAWNZERA product sales ($26.6M) and TRYNGOLZA sales ($4.6M).
• Expense Increase: Operating expenses rose 19% to $370.2M. Selling, General, and Administrative (SG&A) expenses increased significantly to $150.4M due to investments in commercialization for TRYNGOLZA, DAWNZERA, and launch preparations for zilganersen.
• Debt Repayment: In April 2026, the company repaid the remaining principal balance of its 0% Convertible Senior Notes due 2026 ($432.5M) at maturity.
• Stock-Based Compensation: Non-cash stock-based compensation expense increased to $45.6M in Q2 2026 from $29.7M in Q2 2025, attributed to higher stock prices on grant dates and increased headcount (1,480 employees vs. 1,166).

Guidance, Outlook, and Risks

• Outlook: Management expects operating expenses to continue increasing through the remainder of 2026 as commercialization activities advance. The company anticipates independent launches of zilganersen for Alexander disease in 2026, pending regulatory approval.
• Clinical Updates:
  • Eplontersen (WAINUA): The CARDIO-TTRansform Phase 3 trial for ATTR-CM missed its primary efficacy endpoint in July 2026.
  • Zilganersen: FDA Priority Review with a PDUFA action date of September 22, 2026.
  • Bepirovirsen (GSK): FDA Priority Review with a PDUFA action date of October 26, 2026.
• Risks:
  • Commercialization: Limited experience in independent commercialization; reliance on third-party partners for key products (SPINRAZA, WAINUA).
  • Regulatory: Risks associated with failing to meet clinical endpoints or obtaining marketing approvals.
  • Intellectual Property: Ongoing patent litigation regarding SPINRAZA (Somerset Therapeutics ANDA) and plozasiran (Arrowhead Pharmaceuticals).
  • Financial: Continued operating losses and dependence on collaborative revenue and cash reserves to fund operations.

Investor Verification Checklist

• Commercial Execution: Verify the uptake and reimbursement status of independently launched products TRYNGOLZA and DAWNZERA.
• Regulatory Milestones: Monitor the FDA decision on zilganersen (September 2026) and bepirovirsen (October 2026).
• Partnership Revenue: Assess the sustainability of R&D revenue streams following the one-time $280M Ono payment in 2025.
• Cash Burn: Review the trajectory of operating expenses against cash reserves ($2.1B) to determine runway without additional financing.
• Patent Litigation: Track the status of the SPINRAZA patent infringement lawsuit filed against Somerset Therapeutics.